文献速递甲状腺核医学肿瘤 PET/CT核素与放射性配体治疗

18F-FDG PET/CT显示免疫联合靶向治疗未分化甲状腺癌显著缓解

18 F-FDG PET/CT Demonstrates Significant Response in Anaplastic Thyroid Carcinoma Treated With Combined Immunotherapy and Targeted Therapy.
PubMed 文献 · Clin Nucl Med · 2026-02-25

本文报道一例51岁女性活检证实的未分化甲状腺癌患者,初诊时存在广泛局部区域病变和肺转移,接受帕博利珠单抗联合仑伐替尼治疗后,用18F-FDG PET/CT评估疗效,显示接近完全代谢缓解。未分化甲状腺癌罕见且侵袭性强、预后差、对常规治疗反应有限,靶向与免疫治疗近年显示改善预后的潜力,18F-FDG PET/CT可用于评估病变范围和监测治疗反应。

要点

  • 未分化甲状腺癌侵袭性强、预后差,常规治疗反应有限。
  • 靶向联合免疫治疗在该例中显示接近完全代谢缓解。
  • 18F-FDG PET/CT可用于评估病变范围和监测疗效。

核心结论

  • 一例未分化甲状腺癌患者接受帕博利珠单抗联合仑伐替尼治疗后,18F-FDG PET/CT显示接近完全代谢缓解。

研究设计与样本

  • 本文为个案报道,对象为一名51岁女性,活检证实为未分化甲状腺癌。

主要发现

  • 该患者初诊时存在广泛局部区域病变和肺转移。
  • 接受帕博利珠单抗联合仑伐替尼治疗后,18F-FDG PET/CT疗效评估显示接近完全代谢缓解。

临床怎么用

  • 18F-FDG PET/CT可作为未分化甲状腺癌评估病变范围和监测治疗反应的工具。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Anaplastic thyroid carcinoma (ATC) is a rare but highly aggressive malignancy with a dismal prognosis and limited responsiveness to conventional therapies. Recent advances in targeted therapy and immunotherapy have shown promise in improving outcomes. 18 F-FDG PET/CT serves as a valuable tool for evaluating disease extent and monitoring therapeutic response in ATC. We present the case of a 51-year-old woman diagnosed with biopsy-proven anaplastic thyroid carcinoma, presenting with extensive locoregional disease and pulmonary metastases on Pembrolizumab and Lenvatinib. 18 F-FDG PET/CT was done for response assessment which showed near complete metabolic response.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Dharmashaktu Y, Rastogi S, Wakankar R, et al. 18 F-FDG PET/CT Demonstrates Significant Response in Anaplastic Thyroid Carcinoma Treated With Combined Immunotherapy and Targeted Therapy. Clin Nucl Med. 2026. PMID: 41739501. doi:10.1097/RLU.0000000000006207

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。